Results 181 to 190 of about 12,392,515 (266)

Treatment outcomes, safety, and characteristics of immune tolerance induction in patients with hemophilia B and inhibitors: a systematic review. [PDF]

Res Pract Thromb Haemost
Yin S, Wu J, Yang W, Mu H, Peng Y, Lu H, Li R, Bi H, Zhou Z.   +8 more
europepmc   +1 more source

Left Atrial Appendage Closure in a Hemophilia B Patient with Atrial Fibrillation. [PDF]

Anatol J Cardiol
Özbebek YE, Ertem AG.
europepmc   +1 more source

Correction to "Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec". [PDF]

CPT Pharmacometrics Syst Pharmacol
europepmc   +1 more source

Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. [PDF]

N Engl J Med
Reiss UM, Davidoff AM, Tuddenham EGD, Chowdary P, McIntosh J, Muczynski V, Journou M, Simini G, Ireland L, Mohamed S, Riddell A, Pie AJ, Hall A, Quaglia A, Mangles S, Mahlangu J, Haley K, Recht M, Shen YM, Halka KG, Fortner G, Morton CL, Gu Z, Hayden RT, Neufeld EJ, Okhomina VI, Kang G, Nathwani AC.   +27 more
europepmc   +1 more source

Gene therapy as an innovative approach to the treatment of hemophilia B-a review. [PDF]

J Appl Genet
Wróblewska K, Bieszczad D, Popławska M, Ziętara KJ, Zajączkowska M, Filip A.   +5 more
europepmc   +1 more source

Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study. [PDF]

Res Pract Thromb Haemost
Astermark J, LeBeau P, Christensson A, Lethagen S, Berntorp E, Shapiro AD, B-Natural Study investigators.   +6 more
europepmc   +1 more source

Reply to a letter from Miesbach and Srivastava: response to hemophilia B gene therapy based on adeno-associated virus serotype 5 antibody status. [PDF]

Res Pract Thromb Haemost
Klamroth R, Monahan PE, Le Quellec S.
europepmc   +1 more source

Therapeutic base editing to generate a gain-of-function F9 variant for hemophilia B.

Blood
Baatartsogt N, Kashiwakura Y, Hiramoto T, Ito R, Sato R, Nagao Y, Naruoka H, Takata H, Hayakawa M, Batjargal K, Togashi T, Hoshino A, Shimizu T, Sato Y, Ishida T, Nureki O, Ohmori T.   +16 more
europepmc   +1 more source

Corrigendum to 'Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial': [RPTH, 103360, January 2026, Volume 10, Issue 1]. [PDF]

Res Pract Thromb Haemost
Klamroth R, Monahan PE, Van der Valk P, Quon D, Kazmi RS, Coppens M, O'Connell N, Pipe SW, von Drygalski A, Afzal S, Gabriel R, Youssar L, Gill S, Jansen N, Wang F, Le Quellec S, Hermans C.   +16 more
europepmc   +1 more source

Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. [PDF]

Nat Med
Xue F, Ju M, Zhu T, Zhou Z, Sun J, Yang L, Yan Z, Zhou H, Du X, Zheng C, Zheng J, Wu X, Du Z, Jiang W, Yang C, Xiao X, Liu W, Yang R, Zhang L.   +18 more
europepmc   +1 more source